Purchase Short-Term Access

Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease
Geno Merli, MD; Theodore E. Spiro, MD; Carl-Gustav Olsson, MD, PhD; Ulrich Abildgaard, MD, PhD; Bruce L. Davidson, MD, MPH; Amiram Eldor, MD; Darlene Elias, MD; Andrew Grigg, MBBS; Dominique Musset, MD; George M. Rodgers, MD, PhD; Arthur A. Trowbridge, MD; Roger D. Yusen, MD; Krystyna Zawilska, MD; Enoxaparin Clinical Trial Group*
Annals of Internal Medicine 2001;134:191-202. doi:10.7326/0003-4819-134-3-200102060-00009

Purchase Online access to this article for 24 hours
Buy Now

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.